Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda to Initiate Additional Trial for Alogliptin
September 7, 2009
- Astellas to Reshuffle Its Drug Discovery Research Functions
September 7, 2009
- Lilly Drops Arzoxifene Based on Initial PIII Data
September 7, 2009
- R&D NEWS IN BRIEF
September 7, 2009
- G&G to Develop Overseas Business in Earnest
August 31, 2009
- Allopurinol + Uralyt Combination Useful for Management of MetS
August 31, 2009
- SSP to Place Top Priority on Operating Profit Rate
August 31, 2009
- R&D NEWS IN BRIEF
August 31, 2009
- REGULATORY NEWS IN BRIEF
August 31, 2009
- Everolimus Approved in EU: Novartis
August 31, 2009
- Japan, China, South Korea Start Working-Level Regulatory Consultations
August 31, 2009
- Korosho to Promote Sharing of Know-how to Promote Use of Generics
August 31, 2009
- Sampling Tests Show Problems with Only 2 of 876 Products
August 31, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 31, 2009
- Leading Generic Houses Post Strong Growth in Both Sales, Profits
August 31, 2009
- CSL Behring Sponsors HAE Study Meetings for Doctors
August 31, 2009
- Levemir Does Not Increase Cancer Risk: Novo Nordisk
August 31, 2009
- Korosho to Start Japanese Version of Sentinel Initiative
August 31, 2009
- BUSINESS NEWS IN BRIEF
August 31, 2009
- Korosho to Prepare GL for Clinical Assessment of Antidepressants
August 31, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…